You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
皓元醫藥(688131.SH):截至2024年末,公司創新藥累計承接了892個項目

格隆匯8月13日丨皓元醫藥(688131.SH)在投資者互動平臺表示,公司的創新藥相關業務,主要服務模式包括爲客戶提供創新藥物臨牀申報所需的質量研究以及樣品製備服務、爲客戶提供臨牀前或者臨牀階段原料藥或中間體的生產製備服務以及已上市專利藥的中間體商業化生產服務。截至2024年末,公司創新藥累計承接了892個項目,主要佈局在中國、日本、韓國、美國和歐洲市場,處於臨牀前及臨牀I期項目居多,部分產品已進入臨牀II期、臨牀III期或者新藥上市申報階段,有力助推了全球創新藥研發產業的進程,未來隨着客戶項目研究的不斷推進,公司項目所處研發階段也會逐漸往下遊延伸。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account